Mechanisms of oxidative stress and vascular dysfunction

Postgraduate Medical Journal

Volumn 79, Issue 930, 2003, Pages 195-200

  Nedeljkovic, Z S ^a   Gokce, N ^a   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINAPRIL; REACTIVE OXYGEN METABOLITE; SELENIUM; TETRAHYDROBIOPTERIN;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; FIBRINOLYSIS; HEART FAILURE; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; THROMBOCYTE ADHESION; THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CELL COMMUNICATION; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VASCULAR DISEASES; VITAMINS;

EID: 0037514194     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.930.195     Document Type: Review

References (51)

1. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endotheiium. N Engl J Med 1990;323:27-36.
2. Gokce N, Keaney JF Jr, Vita JA. Endotheliopathies: clinical manifestations of endothelial dysfunction. In: Loscalzo J, Shafer AI, eds. Thrombosis. and hemorrhage. 2nd Ed. Baltimore: Williams and Wilkins, 1998: 901-24.
3. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
4. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
5. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-7.
6. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
7. Keaney JF Jr, ed. Oxidative stress and vascular disease. New York: Kluwer Academic Publishers, 2000.
8. Kojda G, Harrison DG. Interactions between NO and reactive oxygen species: pathophysiological importance in atheroslrerosis, hypertension, diabetes, and heart failure. Cardiovasc Res 1999;43:562-71.
9. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.
10. Ohora Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
11. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations in vasomotor tone. J Clin Invest 1996;97:1916-23.
12. Meredith IT, Anderson TJ, Yeung AC, et al. Superoxide dismutase restores endothelial vasodilator function in human coronary arteries in vivo. Circulation 1993;88:1-467 (abst).
13. Mugge A, Elwell JK, Peterson TE, et al. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 1991;260:C219-25.
14. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
15. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
16. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039-46.
17. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelium-derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992;89:10-18.
18. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996;20:707-27.
19. Wolin M. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 2000;20:1430-42.
20. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 2000;87:840-4.
21. Griendling KK, Sorescu D, Ushio-Fukai M. NADP(H) oxidase. Role in cardiovascudar biology and disease. Circ Res 2000;86:494-501.
22. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997;95:588-93.
23. Guzik T, West N, Black E, et al. Vascular superoxide production by NAD(P)H oxidase. Association with endothelial dysfunction and clinical risk factors. Circ Res 2000;86:e85-90.
24. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 2002;105:1429-35.
25. Cardillo C, Kilcoyne CM, Cannon RO, et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997;30:57-63.
26. Ueda S, Matsuoka H, Miyazaki H, et al. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 2000;35:71-5.
27. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997;99:41-6.
28. Gokce N, Keaney JF Jr, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-40.
29. Timimi FK, Ting HH, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998;31:552-7.
30. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85:753-66.
31. Valen G, Yan Z, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001;38:307-14.
32. 2 for platelet-derived growth factor signal transduction. Science 1995;270:298-301.
33. Irani K. Oxidant signaling in vascular cell growth, death, and survival. A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-83.
34. Channon KM. Oxidative stress and coronary plaque stability. Arterioscler Thromb Vasc Biol 2002;22:1751-2.
35. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
36. Azumi H, Inoue N, Ohashi Y, et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris. Important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2002;22:1838-44.
37. Galis ZS, Asanuma K, Godin D, et al. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998;97:2445-53.
38. Diaz MN, Frei B, Vita JA, et al. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-17.
39. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
40. Anonymous. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
41. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:154-60.
42. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
43. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo- controlled trial. Lancet 2002;360:23-33.
44. Steinberg D, Witztum J. Is the oxidative modification hypothesis relevant to human atheroslcerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002;105:2107-11.
45. Munzel T, Keaney JF Jr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001;104:1571-4.
46. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [see comments] [published erratum appears in N Engl J Med 2000;342:748]. N Engl J Med 2000;342:145-53.
47. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65.
48. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001;103:919-25.
49. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19.
50. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID] Study Group. Prevention of cardiovascudar events and death with pravastatin in patients with coronary heart disease and a broad range of initial choresterol levels. N Engl J Med 1998;339:1349-57.
51. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo- controlled trial. Lancet 2002;360:7-22.